reversal agent

reversal agent

Anesthesiology Any drug used to reverse the effects of anesthetics, narcotics or potentially toxic agents Examples Antilirium, digibind, mestinon, narcan, neostigmine, protopam, pyridostigmin, romazicon, tensilon. See Induction agent.
References in periodicals archive ?
Portola Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has communicated a positive trend vote on the Marketing Authorisation Application for andexanet alfa, a Factor Xa-inhibitor reversal agent, and a negative trend vote for betrixaban, an oral, once-daily Factor Xa inhibitor.
However, the acute care of patients taking NOACs can be challenging, because only dabigatran has an approved reversal agent, and none have readily available, reliable measurement assays.
announced that an abstract detailing interim results from the Companys ongoing Phase 3b/4 trial of its investigational Factor Xa reversal agent, andexanet alfa, has been accepted for oral presentation during a late-breaking clinical trial session at the American College of Cardiologys 67th Annual Scientific Session & Expo (ACC.
Since the time of administration of reversal agent, patients in Desflurane group had significantly faster emergence and obeying commands than those in Sevoflurane group, however, this faster wakeup failed to translate into early readiness for discharge from the hospital.
With this support from Daiichi Sankyo, we will be able to improve our ability to gather data on AndexXa as a reversal agent for edoxaban.
Physicians and patients choosing Pradaxa may have added assurance knowing that it is the only novel oral anticoagulant with more than five years of use in clinical practice and a specific reversal agent.
Heart rate, mean arterial pressure and intraocular pressure were measured at baseline, before the induction (T1), after the application of reversal agent (T2), and 1 (T3), 3 (T4), 5 (T5) and 10 (T6) minutes after the extubation.
M2 EQUITYBITES-October 20, 2015-Boheringer Inglelheim's Praxbind(R) (idarucizumab), Specific Reversal Agent for Pradaxa(R) (dabigatran etexilate) approved by US FDA
2013; O'Riordan, 2014; Portola Pharmaceuticals, 2014) that is being developed as a direct reversal agent for patients receiving a Factor Xa inhibitor who suffer a major bleeding episode or who require emergency surgery.
The second major driver will be the approval and launch of the first antidotes for the NOACs, which will alleviate physician and patient concerns regarding a lack of a reversal agent in the event of uncontrolled bleeding, and will increase overall uptake.
While a 4-factor prothrombin complex concentrate (PCC) was recently FDA approved for the reversal of warfarin in patients with acute, major bleeding, (23) no specific NOAC reversal agent (or "antidote") is available for clinical use to date.